The Laryngoscope · 2026
Office-Based Blue Laser Therapy and Steroid Injection of Hemorrhagic and Nonhemorrhagic Vocal Fold Polyp.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hamdan Abdul-Latif, Abou Raji Feghali Patrick, Ghzayel Lana, Lababidi Ghena, Sarkis Valerie, Hosri Jad, Alam Elie, Mourad Marc
Аннотация
OBJECTIVE: To investigate the correlation between the morphology of vocal fold polyps, hemorrhagic versus nonhemorrhagic, and treatment outcome following office-based blue laser therapy with intralesional steroid injection.
METHODS: All the medical records and video recordings of patients diagnosed with vocal fold polyps who underwent office-based blue laser therapy with intralesional steroid injection at a tertiary referral center between June 2023 and August 2025 were reviewed. Vocal fold polyps were classified as hemorrhagic versus nonhemorrhagic. The treatment outcome measures included the Voice Handicap Index-10 (VHI-10) score, acoustic parameters, maximum phonation time (MPT), and disease regression. The mean follow-up period was 12.79 ± 12.31 weeks.
RESULTS: A total of 29 patients with vocal fold polyps were included in the study. Twenty-one patients had hemorrhagic polyps, while the remaining had nonhemorrhagic polyps. No significant differences in the demographic variables were noted between the two subgroups. The mean VHI-10 score in the hemorrhagic polyp subgroup decreased by 10.2 ± 6.76 points, compared to 6.33 ± 7.14 points in the nonhemorrhagic subgroup (p = 0.208). There was a significant difference in complete disease regression between the hemorrhagic and nonhemorrhagic subgroups (95.2% vs. 62.5% p = 0.022). No significant differences were observed in any of the acoustic parameters between the two subgroups except for jitter (p = 0.017).
CONCLUSION: The results of this investigation indicate that hemorrhagic vocal fold polyps respond better to office-based blue laser therapy with intralesional steroid injection than nonhemorrhagic polyps.
METHODS: All the medical records and video recordings of patients diagnosed with vocal fold polyps who underwent office-based blue laser therapy with intralesional steroid injection at a tertiary referral center between June 2023 and August 2025 were reviewed. Vocal fold polyps were classified as hemorrhagic versus nonhemorrhagic. The treatment outcome measures included the Voice Handicap Index-10 (VHI-10) score, acoustic parameters, maximum phonation time (MPT), and disease regression. The mean follow-up period was 12.79 ± 12.31 weeks.
RESULTS: A total of 29 patients with vocal fold polyps were included in the study. Twenty-one patients had hemorrhagic polyps, while the remaining had nonhemorrhagic polyps. No significant differences in the demographic variables were noted between the two subgroups. The mean VHI-10 score in the hemorrhagic polyp subgroup decreased by 10.2 ± 6.76 points, compared to 6.33 ± 7.14 points in the nonhemorrhagic subgroup (p = 0.208). There was a significant difference in complete disease regression between the hemorrhagic and nonhemorrhagic subgroups (95.2% vs. 62.5% p = 0.022). No significant differences were observed in any of the acoustic parameters between the two subgroups except for jitter (p = 0.017).
CONCLUSION: The results of this investigation indicate that hemorrhagic vocal fold polyps respond better to office-based blue laser therapy with intralesional steroid injection than nonhemorrhagic polyps.